This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pacira's (PCRX) Q2 Earnings Miss Estimates, Revenues In Line
by Zacks Equity Research
Pacira (PCRX) misses on earnings for the second quarter of 2020 while its revenues meet the mark.
Pacira (PCRX) Misses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Pacira (PCRX) delivered earnings and revenue surprises of -25.00% and -0.03%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
PCTEL (PCTI) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Despite a robust balance sheet, PCTEL (PCTI) is likely to have witnessed top- and bottom-line contractions due to COVID-19 triggered headwinds in the second quarter.
What's in Store for Avenue Therapeutics (ATXI) in Q2 Earnings?
by Zacks Equity Research
Avenue Therapeutics' (ATXI) sole pipeline candidate, tramadol, is under review. With lower clinical activities, operating expenses are likely to have declined during the second quarter.
Aldeyra (ALDX) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Aldeyra's (ALDX) pipeline progress will be in focus when it reports Q2 results later in the week.
CytoDyn (CYDY) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
CytoDyn's progress on its lead candidate, leronlimab, will be in focus when it reports Q4 results.
Actinium (ATNM) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Actinium's (ATNM) lead candidate, Iomab-B, being evaluated for acute myeloid leukemia will be in focus when the company reports second-quarter earnings.
Onconova (ONTX) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Investors will focus on pipeline updates when Onconova (ONTX) reports Q2 results.
Teva (TEVA) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
On Teva's (TEVA) second-quarter conference call, investors will look for updates on the extent to which the coronavirus pandemic may have impacted sales of its products
Will Pacira (PCRX) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Pacira (PCRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
3 Reasons Why Pacira (PCRX) Is a Great Growth Stock
by Zacks Equity Research
Pacira (PCRX) possesses solid growth attributes, which could help it handily outperform the market.
Zoetis (ZTS) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Zoetis (ZTS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Top Ranked Momentum Stocks to Buy for July 21st
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, July 21st
Vaxart (VXRT) Catches Eye: Stock Jumps 7.9%
by Zacks Equity Research
Vaxart (VXRT) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Zacks.com featured highlights include: Nautilus, Ameresco, Canadian Solar, Emergent BioSolutions and Pacira BioSciences
by Zacks Equity Research
Zacks.com featured highlights include: Nautilus, Ameresco, Canadian Solar, Emergent BioSolutions and Pacira BioSciences
5 Stocks With Recent Price Strength Despite Market Volatility
by Nalak Das
Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
Entasis Therapeutics (ETTX) Jumps: Stock Rises 5.4%
by Zacks Equity Research
Entasis Therapeutics (ETTX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Otonomy (OTIC) Catches Eye: Stock Jumps 9.1%
by Zacks Equity Research
Otonomy (OTIC) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
Verrica (VRCA) in Focus: Stock Moves 8.9% Higher
by Zacks Equity Research
Verrica (VRCA) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Top Ranked Momentum Stocks to Buy for July 10th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, July 10th
The Zacks Analyst Blog Highlights: Alpine Immune Sciences, Actinium Pharmaceuticals, Pacira BioSciences and Translate Bio
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Alpine Immune Sciences, Actinium Pharmaceuticals, Pacira BioSciences and Translate Bio
Pacira (PCRX) Provides Preliminary Results for Second Quarter
by Zacks Equity Research
Pacira (PCRX) reports preliminary results for the second quarter of 2020. The company's product sales are hurt by the COVID-19 pandemic. The stock fell in pre-market trading.
4 Small Drug Stocks Worth Betting on Amid Coronavirus Woes
by Zacks Equity Research
Here we discuss four small stocks from the drug sector, which hold potential for a good run amid the coronavirus crisis.
Will Pacira BioSciences Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor of Pacira BioSciences
Pacira (PCRX) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Pacira (PCRX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.